Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from efavirenz (Atripla) to raltegravir + Truvada for CNS toxicity
2010-018878-21Phase 3Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of raltegravir and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by St Stephen's AIDS Trust. Primary endpoints: Rate of neuropsychiatric and CNS toxicity at 4 weeks and Rate of neuropsychiatric and CNS toxicity at 12 weeks. Started Jun 2010; status: completed.
02
Drugs
raltegraviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-018878-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018878-21.